Hanyang University ERICA announced on the 2nd that it has opened the 'Drug Metabolism Microbiomics Research Center' and will engage in related research and development as well as human resource training.


Officials are taking a commemorative photo at the "Drug Metabolism Microbiomics Research Center Opening Ceremony" held at the College of Pharmacy, Hanyang University ERICA. <br>[Photo by Hanyang University ERICA]

Officials are taking a commemorative photo at the "Drug Metabolism Microbiomics Research Center Opening Ceremony" held at the College of Pharmacy, Hanyang University ERICA.
[Photo by Hanyang University ERICA]

View original image

The research center was established to elucidate the interactions between the microbiome (microorganisms), which has recently gained attention in the pharmaceutical bio industry, and drugs, aiming to propose optimal drug therapy strategies. To this end, 13 participating researchers with expertise and research capabilities in pharmacokinetics, pharmacodynamics, and microbiomics, along with 60 students and researchers, are involved.


Additionally, the research center includes Seegene Medical Foundation, a molecular diagnostics specialist institution, and J2H Biotech, a synthetic drug new drug development specialist institution, to conduct joint research for the successful clinical application of basic research.


President Lee Ki-jung said, "Although the ERICA College of Pharmacy has a relatively short history, it has been recognized for its excellence through securing significant group research projects. We expect that through the opening of this research center, the education and research capabilities of the ERICA College of Pharmacy will grow to the next level and develop into the nation's top prestigious college of pharmacy."



Research Center Director Yoo Hye-hyun stated, "We aim to contribute to maximizing drug therapeutic efficacy and minimizing side effects by elucidating changes in effective drug concentration, regulation of drug efficacy expression, and mechanisms caused by the human microbiome, developing microbiome markers and control platforms for personalized drug therapy and improving the success rate of new drug development."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing